Alexandra Garcia, Emilie Dugast, Sita Shah, Jérémy Morille, Christine Lebrun-Frenay, Eric Thouvenot, Jérôme De Sèze, Emmanuelle Le Page, Sandra Vukusic, Aude Maurousset, Eric Berger, Olivier Casez, Pierre Labauge, Aurélie Ruet, Catarina Raposo, Fabien Bakdache, Régine Buffels, Fabienne Le Frère, Arnaud Nicot, Sandrine Wiertlewski, Pierre-Antoine Gourraud, Laureline Berthelot, David Laplaud
BACKGROUND AND OBJECTIVES: Ocrelizumab (OCR), a humanized anti-CD20 monoclonal antibody, is highly efficient in patients with relapsing-remitting multiple sclerosis (RR-MS). We assessed early cellular immune profiles and their association with disease activity at treatment start and under therapy, which may provide new clues on the mechanisms of action of OCR and on the disease pathophysiology. METHODS: A first group of 42 patients with an early RR-MS, never exposed to disease-modifying therapy, was included in 11 centers participating to an ancillary study of the ENSEMBLE trial (NCT03085810) to evaluate the effectiveness and safety of OCR...
May 2023: Neurology® Neuroimmunology & Neuroinflammation